The corrected exchange ratio (1:1 post-split vs. previously stated 1:4) is a material clarification that significantly improves the implied merger value for IBO shareholders. Monitor for the definitive proxy statement and stockholder vote date. The reverse split alone does not guarantee NYSE American compliance or deal closure — watch for any further delisting notices or merger termination risks.
Price Chart
Executive Summary
Impact Biomedical (IBO) is implementing a 1-for-12.62 reverse stock split effective September 23, 2026, to support its proposed merger with Zoar Ltd and regain NYSE American compliance. A corrected press release clarifies the merger exchange ratio is 1 Zoar share for each post-split IBO share, correcting an earlier error that stated 1-for-4. The merger remains subject to stockholder approval and regulatory conditions, with no assurance of completion.
Key Financial Metrics
Key Facts
- Reverse stock split at 1-for-12.62 ratio, effective 12:01 a.m. ET on September 23, 2026.
- Outstanding shares will decrease from ~107.8 million to ~8.5 million.
- Corrected merger exchange ratio: 1 Zoar share per 1 post-split IBO share (previously misstated as 1-for-4).
- Split is intended to support the proposed merger with Zoar Ltd and regain NYSE American listing compliance.
- No assurance the split will achieve compliance or that the merger will close.
- Zoar Ltd has filed an F-4 registration statement; a definitive proxy statement/prospectus will be mailed to IBO stockholders.
- Merger expected to create a pharmaceutical company focused on active pharmaceutical ingredients and intermediates.
Financial Impact
Reverse stock split reduces share count from ~107.8M to ~8.5M, a 92% reduction. No change in proportional ownership. Merger exchange ratio corrected to 1:1 post-split.
Risk Factors
- Reverse split may not achieve NYSE American continued listing compliance.
- Merger with Zoar Ltd may not be approved by stockholders or close.
- Corrected exchange ratio could create volatility as the market re-prices the deal.
- No financial terms of the merger (valuation, consideration) are disclosed in this filing.
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (ZOAR) — Batch item 1 | 0001493152-26-042640 |
| Exhibit: ex99-1.htm | 0001493152-26-042644 |
| Document: 0001493152-26-042640-index-headers.html | 0001493152-26-042640 |
| Document: 0001493152-26-042640-index.html | 0001493152-26-042640 |
| Document: 0001493152-26-042640.txt | 0001493152-26-042640 |
| 425 Filing (ZOAR) — Batch item 6 | 0001493152-26-042644 |
| Document: 0001493152-26-042644-index-headers.html | 0001493152-26-042640 |
| Document: 0001493152-26-042644-index.html | 0001493152-26-042640 |
| Document: 0001493152-26-042644.txt | 0001493152-26-042640 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | EFFECT | — | awaiting T+20 | — | — |
Sep 14, 2026 5w ago | 425 | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers